Company / R&D Expense
Insulet Corporation R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$301.1M
FY2025
5-year range
$160.1M / $301.1M
FY2021-FY2025
Trend
+37.1%
vs FY2024
Sector context
#24 of 105
Health Care
What the data says
Insulet Corporation's r&d expense of $301M is higher than 77% of companies in the Health Care sector (FY2025). R&D Expense has increased for 9 consecutive years, from $56M in FY2016 to $301M in FY2025.
Based on SEC 10-K filings.
$301M in FY2025 with a 5-year CAGR of +15.5%. Top quartile in the Health Care sector.
Improved from $205M to $301M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +18.7%
- 5-Year CAGR
- +15.5%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 105This company $301.1M Sector average $284.2M
▼
+5.9% above sector average
Key checks
Key Insights
- Insulet Corporation's r&d expense has grown for 9 consecutive years.
- 5-year CAGR of +15.5%, indicating consistent growth.
- In FY2025, r&d expense increased 37.1% year-over-year.
- Ranks #24 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $301.1M | +37.1% |
| FY2024 | $219.6M | +7.1% |
| FY2023 | $205.0M | +13.8% |
| FY2022 | $180.2M | +12.6% |
| FY2021 | $160.1M | +9.1% |
| FY2020 | $146.8M | +11.0% |
| FY2019 | $132.3M | +39.6% |
| FY2018 | $94.8M | +25.2% |
| FY2017 | $75.7M | +35.9% |
| FY2016 | $55.7M | +28.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026